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folic acid supplements use included awareness that folic acid prevent neural tube 
defects and perceived benefits that folic acid can prevent neural tube defects, and 
receiving advice from the doctor about using birth control. CONCLUSIONS: Although 
the women in this survey were aware and have knowledge that folic acid prevent 
birth defects; a large number of them reported not taking folic acid supplements. The 
reported consumption of folic acid was associated with the awareness and perceived 
benefits that folic acid use prevent NTDs. Therefore, it is important to raise aware-
ness about the beneficial effects of folic acid use among women of childbearing age.
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OBJECTIVES: To examine quality-of-life (QOL) predictors of treatment continua-
tion on eslicarbazepine acetate (ESL) monotherapy (1200 or 1600 mg/day) among 
subjects with partial epilepsy not well-controlled by current anti-epileptic drugs 
(AEDs). METHODS: Analysis of efficacy and QOL data from the pooled per-protocol 
population (n= 200) of two 18-week randomized clinical trials of ESL (045 and 046), 
both with an 8-week taper/conversion period and a 10-week efficacy period. The 
primary efficacy endpoint for these trials was study exit due to: worsening sei-
zure type, increased seizure frequency (SF), or investigator judgment. Predictors 
of monotherapy treatment continuation after 10 weeks were examined using 
stepwise logistic regression. Covariates included ESL dose, demographics, dis-
ease duration, baseline SF, baseline AEDs, number of AEDs, change in SF, and 
changes in the QOLIE-31 subscale scores (Cognitive Functioning, Emotional Well-
being, Energy/Fatigue, Medication Effects, Overall QOL, Seizure Worry [SW], and 
Social Functioning) during the taper/conversion period. A separate model included 
change in SF to test whether predictors were independent of efficacy during taper/
conversion. RESULTS: Change in SW during the 8-week taper/conversion period 
was the only predictor of remaining on ESL monotherapy. Mean change was 9.6 
(SD: 20.98) for 181 subjects remaining on monotherapy, indicating a reduction in 
worry. Mean change for 19 subjects who exited was -4.8 (SD: 20.79). Each point 
improvement in SW was associated with a 4% increase in the odds of remaining 
on monotherapy (odds ratio [OR]: 1.04; 95% CI: 1.01, 1.06). Results were similar with 
inclusion of SF change in this model (OR: 1.03; 95% CI: 1.01, 1.06). CONCLUSIONS: 
In this pooled, per-protocol population analysis, change in a subject’s level of 
seizure worry was moderately predictive of remaining on ESL monotherapy. This 
may be a surrogate for severity of epilepsy and the value of such predictors needs 
additional research and assessment.
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OBJECTIVES: Research examining epilepsy treatment satisfaction is lacking. The 
aim of this study is to compare treatment satisfaction among patients with epilepsy 
treated either with monotherapy or adjunctive therapy. METHODS: Data from the 
2011-2013 U.S. National Health and Wellness Survey (NHWS) were analyzed. The 
NHWS is a self-administered, internet-based survey of a nationwide sample of 
adults stratified to represent the demographic composition of the U.S. population. 
Patients who reported being treated with an antiepileptic drug (AED) for epilepsy 
were grouped as using monotherapy (one Rx) or adjunctive AED therapy (two or 
more Rxs). Patients provided information on treatment satisfaction with current 
epilepsy prescription medication (1 [extremely dissatisfied] to 7 [extremely satis-
fied]), demographics, and health characteristics (e.g., age, comorbidities [Charlson 
comorbidity index], epilepsy severity). Pairwise comparisons (Bonferroni adjusted) 
examined whether patients on monotherapy vs. adjunctive therapy differed in 
treatment satisfaction. RESULTS: Among 1,126 epilepsy patients (mean age= 46.33; 
47.70% female), 744 were on monotherapy (66.07%), 286 on two AEDs (25.40%), 65 on 
three AEDs (5.77%), and 31 on four or more AEDs (2.75%). Compared to monotherapy 
patients, treatment of patients with an increasing number of concomitant AEDs was 
associated with greater comorbidity burden (4+Rxs: 3.00 vs. monotherapy: 0.93), 
higher percentage of severe epilepsy (4+Rxs: 41.90% vs. monotherapy: 10.60%), and 
higher seizure frequency (4+Rxs: 35.50% vs. monotherapy: 7.30% for frequency > 
1/week), all p< .05. Patients on monotherapy (5.93) had higher treatment satisfac-
tion than patients on adjunctive therapy (4+Rxs: 4.78), p< .05. Additionally, among 
adjunctive therapy patients, those on 2Rxs (5.79) had higher satisfaction than those 
on 4+Rxs (4.78), p< .05. CONCLUSIONS: In this study, monotherapy patients were 
more satisfied with their epilepsy treatment than adjunctive therapy users. The 
lower satisfaction levels among adjunctively-treated patients may be associated 
with the number of concomitant AEDs, seizure severity or frequency, comorbid 
conditions, or a combination of these factors.
PND57
Quality of life iN Neuromyelitis oPtica: a systematic review
Likhar N., Dang A.
MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
OBJECTIVES: Neuromyelitis optica (NMO) is an inflammatory CNS disease, that pre-
sents with severe optic neuritis and transverse myelitis. It is often accompanied by 
severe motor and sensory disability. In the past few years, NMO has gained lot of inter-
est and shares a controversial relationship with multiple sclerosis (MS). It is not yet 
known whether NMO differs in its effect on quality of life (QoL) when compared with 
MS. We aimed to evaluate the QoL in patients with NMO by conducting a systematic 
regular sleeplessness symptoms and insomnia/SD. More women were affected; 
67% of patients age 65-74 (2.5 M) and 73% of patients age 75+ (1.9 M) were female 
(p’s< 0.05). Approximately 1.1 M patients age 65+ self-reported using a product con-
taining DPH/DOX. Women were more likely to use DPH/DOX than men (21% (526 
K) vs. 12% (150 K) age 65-74 (p< 0.05); 19% (348 K) vs. 11% age 75+ (76 K) (p> 0.05)). 
However, men using DPH/DOX reported taking it more mean days per month (14.4 
vs. 11.3 age 65-74 (p< 0.05); 18.4 vs. 13.7 age 75+ (p> 0.05)). CONCLUSIONS: An esti-
mated one million adults age 65+ self-reported using DPH/DOX, many on a regular 
basis. Women composed a larger proportion of users, though men reported using 
these products more frequently. Further study on the use and safety of these OTC 
agents in older populations is recommended.
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OBJECTIVES: Familial Amyloidotic Polyneuropathy (FAP) is a rare, inherited, progres-
sively debilitating disease with a high unmet medical need. The purpose of this 
analysis is to assess the impact of FAP on healthcare resource utilization, quality 
of life, employment status, and activities of daily living (ADLs). METHODS: A Phase 
2 open-label extension study of patisiran in FAP patients was utilized to collect 
patient-reported outcomes, including EQ-5D, Rasch-built Overall Disability Scale 
(R-ODS), and a healthcare resource utilization questionnaire. RESULTS: The study 
included 27 patients, 18 males and 9 females, 29-77 years of age. Baseline data 
are presented for 14 patients with a Polyneuropathy Disability (PND) Score I and 
13 patients with a PND Score ≥ II. Characterized by FAP Stage, 24 patients are FAP 
Stage 1 and 3 patients are FAP Stage 2. Two patients (PND Score ≥ II) reported a total 
of six hospitalizations due to FAP in the past 12 months, each for 3 or more nights 
in duration. Mean EQ-5D scores were 0.82 (PND Score I) and 0.74 (PND Score ≥ II). 
Patients reported their perceived health status on the EQ-VAS with mean scores of 
75 (PND Score I) and 60 (PND Score ≥ II). Ten patients (8/10 PND Score ≥ II) reported 
they cannot work because of FAP. Patients also reported inability to perform various 
ADLs. Most commonly, 77% of patients with PND Score ≥ II cannot stand for hours 
(14% in PND Score I) and 69% cannot run (21% in PND Score I). CONCLUSIONS: FAP 
patients experience considerable burden of illness early in the course of disease 
and this burden increases with disease progression. The factors described will be 
influential in the development of a comprehensive FAP cost-consequence analysis. 
Additional parameters may also be needed to fully capture the totality of burden.
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OBJECTIVES: Despite the wealth of qualitative studies exploring the experiences 
of patients with cystic fibrosis (CF), currently no conceptual model of CF exists. 
Conceptual models are a valuable way to communicate relevant patient-centered 
concepts and the relationships between them, and form an important frame-
work for understanding what to measure in clinical trials and practice. This study 
aimed to use patient-derived qualitative insights to develop a conceptual model 
of CF. METHODS: A targeted literature review was performed to identify qualita-
tive studies describing the lived-experience of patients (aged ≥ 6 years) with CF. 
CF social media forums were also reviewed to supplement the published data by 
providing patient-derived quotes where none existed in the literature. Data were 
coded using Atlas.Ti software, and analysed to develop the conceptual model. Where 
possible, any differences in concepts according to age were identified. RESULTS: 
31 qualitative articles and 26 social media entries were reviewed, containing data 
from patients aged 6-67 years. Data from these sources were synthesized to develop 
a conceptual model of CF, comprising: 23 symptom concepts categorized into 3 
domains (respiratory, gastrointestinal/urinary, flu-like symptoms), 28 impact con-
cepts categorised into 9 domains (social, financial difficulties, psychological, future 
concerns, daily activities, emotional, physical functioning, work or school, sleep), 
and 5 treatment satisfaction concepts categorised into 2 domains (satisfaction with 
treatment administration, treatment adherence). Differences in impact concepts 
were apparent based on the patient’s age, e.g. bullying was only reported by children 
and financial issues only by adults. CONCLUSIONS: To our knowledge, this is the 
first patient-centered conceptual model for CF, reflecting the symptom and impact 
burdens of CF on patients’ lives as identified through qualitative patient-derived 
data. As such, this model provides an important critical framework to assess the 
conceptual relevance and patient-centeredness of outcome assessments ahead of 
selection for future clinical trials and clinical practice.
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OBJECTIVES: To assess the factors that affect taking folic acid supplements among 
women of childbearing age. METHODS: A cross-sectional online survey was con-
ducted among women of childbearing age at West Virginia University (n= 179) from 
January to March 2014. Multinomial logistic regression model was used to examine 
the factors that affect taking folic acid supplements. RESULTS: Around 42% of par-
ticipants reported taking folic acid supplements. Factors that were associated with 
